



CURRICULUM VITAE

Name: Neil Harrison Bander

Place of Birth: Boston, MA

Nationality: U.S.A.

Education:

Johns Hopkins University
1969, B.A. (Biology)

University of Connecticut Medical School
1974, M.D.

Postdoctoral Training:

Intern, 1974-75; Junior Resident, 1975-76; Resident, General
Surgery, 1976-77, New York University-Bellevue Medical Center

Resident, Urology, 1977-78; Senior Resident, Urology, 1978-79;
Chief Resident, Urology, 1979-80, University of Connecticut Medical Center

Research Fellow, Immunology, Sloan-Kettering Institute for Cancer
Research, 1980-83

Fellow, Urologic Oncology, Memorial Hospital, 1982-83

Academic, Hospital and Research Positions and Appointments:

Professor of Urology, Weill Medical College of Cornell University;
Incumbent, Bernard and Josephine Chaus Chair in
Urologic Oncology; Surgical Director of Urologic Oncology

Attending Surgeon, Department of Urology, New York Presbyterian
Hospital-Cornell University Medical Center

Research Associate, Memorial Sloan-Kettering Cancer Center, 1984-85;
Assistant Member, 1985-present

Clinical Assistant Surgeon, Urology Service, Memorial Hospital, 1985-
present; Clinical Assistant Surgeon, Clinical Immunology Service, 1985-
present

Research Associate, Sloan-Kettering Institute for Cancer Research, 1983-
present

Assistant Member, Ludwig Institute for Cancer Research
at Memorial Sloan-Kettering Cancer Center), 1992-present

Licensed Physician: State of New York (#126232)

Board Certification: Urology (1983)

Scientific and Medical Societies:

Fellow, American College of Surgery
American Urological Association
Association for Academic Surgery
Society of Urologic Oncology
American Society of Clinical Oncology
American Association of Cancer Research
Member, Medical Advisory Board, National Kidney Cancer Association
Cancer and Leukemia Group B (CALGB), GU Committee, 1989-94
Organizing Committee, IXth International Conference on Monoclonal
Antibody Immunoconjugates, 1993-94
Chair, Medical Research Committee, New York Section, American
Urological Association, 1994-95
Member, American Association of Clinical Urologists, Inc.

Honors and Awards:

American Cancer Society Pre-doctoral Research Fellowship,
Dana-Farber Cancer Center/Harvard Medical School (mentor: Sidney
Farber, M.D.), 1969-70
Mosby Scholarship Award, University of Connecticut Medical School,
1973-74
NIH Immunobiology Fellowship, Memorial Sloan-Kettering Cancer
Center (mentor: Lloyd J. Old, M.D.), 1980-83
New York Academy of Medicine, Ferdinand C. Valentine Fellow in
Urology (mentor: Willet F. Whitmore, Jr., M.D., Memorial Sloan-
Kettering Cancer Center, 1982-83
Society of Surgical Oncology Ewing Research Award, 1983
Deutsche Gesellschaft für Urologie (German Urological Association)
Prize for Experimental Research, 1989
Visiting Lecturer, Japanese Urological Association, 1992
Association for the Cure of Prostate Cancer (CaP Cure) Award, 1993,
1994, 1995, 1996, 1997, 1998

Other Activities:

Member, Cancer Clinical Investigation Review Committee (CCIRC) -
Ad Hoc Committee on Urologic Oncology Cooperative Groups, National
Institutes of Health, 1988
Site Review Committee, National Cancer Institute, 1988
Cancer Care & Research Committee, New York Hospital-Cornell Medical
Center, 1994-present
Advisory Board, Prostate Cancer Infolink, 1995-present
Scientific Advisory Board, BZL Biologics, Inc., 1995-present
Human Genetics and Gene Therapy Working Group, New York Hospital-
Cornell Medical Center, 1996-present
Review Committee, Cancer Research Institute's Prostate Cancer Initiative
Clinical Trials Program, 1996, 1997
Reviewer, Ohio Cancer Research Associates, 1995, 1997
CaP CURE Grant Review Committee, 1997
Consultant/Science Advisory Board - Prostagren, Inc., 1997-
Reviewer, Department of Defense-Prostate Cancer Research Program,
Immunology Grant Review Panel #1, January, 1998
Immunology Grant Review Panel #2, May, 1998
Member, Urologic Oncology Branch's Tenure Track Urologic Surgeon Search
Committee, National Cancer Institute, 1998
Consultant in Urology/Urological Oncology, Strang Cancer Prevention Center,
July 1, 1999-June 30, 2000.

Home Address: 2 Hemlock Hills
Chappaqua, New York 10514

Office Address: Department of Urology, Room E-300, Box 23
New York Hospital-Cornell University Medical Center
525 East 68 Street
New York, NY 10021

Telephone: (212) 746-5493 FAX: (212) 746-8941

Soc. Sec. #: 030-38-7526

Marital Status: Married **Spouse's Name:** Karen Bander, Ph.D.

Dependents #: Gregory Bander (08/27/85)
Evan Bander (11/10/88)

BIBLIOGRAPHY

1. Conroy MC, Bander NH and Lepow IH: Effect of intradermal injections in the rat of purified proteases from *Streptococcus* and *Serratia marescens*. *Proc Soc Exp Biol Med* 1975; **150**:801-805.
2. Bander NH: Comparison of antigen expression of human renal cancer *in vivo* and *in vitro*. *Cancer* 1984; **53**:1235-1239.
3. Cordon-Cardo C, Bander NH, Fradet Y, Finstad CL, Whitmore WF Jr, Lloyd KO, Oettgen HF, Melamed MR and Old LJ: Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. *J Histochem Cytochem* 1984; **32**:1035-1040.
4. Bander NH, Welt S, Houghton AN, Lloyd KO, Grando R, Yeh S, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF and Old LJ: Radionuclide imaging of human renal cancer with labeled monoclonal antibodies. *Surg Forum* 1984; **35**:652-655.
5. Bander NH: Renal cancer: A model system for the study of human neoplasia. *In: Contributions in Oncology*, Riethmuller G, Koprowski H, von Kleist S, eds. (S. Karger, Basel) 1984.
6. Finstad CL, Cordon-Cardo C, Bander NH, Whitmore WF Jr, Melamed MR and Old LJ: Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. *Proc Natl Acad Sci USA* 1985; **82**:2955-2959.
7. Bander NH, Cordon-Cardo C, Finstad CL, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF, Melamed MR and Old, LJ: Immunohistologic dissection of the human kidney using monoclonal antibodies. *J Urol* 1985; **133**:502-505.
8. Bander NH: Study of the normal human kidney and kidney cancer with monoclonal antibodies. *Uremia Invest* 1985; **8**:263-273.
9. Fleischmann J, Heston W, Bauer W, Ratliff T, Bander NH and Fair W: Human renal cell carcinoma xenograft morphology, growth and chemosensitivities. *J Urol* 1985; **134**:570-574.
10. Bander NH and Cordon-Cardo C: Monoclonal antibody defined markers of human renal cancer. *In: Monoclonal Antibodies to Tumor Markers*, Sell S, Reisfeld R, eds.(Humana Press, Clifton, NJ), 1985.

11. Rosenberg S, Bander NH and Herr H: Testis tumors. *In: Current Therapy in Endocrinology*, Krieger D, Bardin W, eds. (BC Decker, Philadelphia, PA) 1985.
12. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, Bander NH, Finstad CL, Cordon-Cardo C, Klotz LH, Old and Rubin RH: Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. *Transplantation* 1986; **41**:593-597.
13. Cordon-Cardo C, Lloyd KO, Finstad CL, McGroarty ME, Reuter VE, Bander NH, Old LJ and Melamed MR: Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. *Lab Invest* 1986; **55**:444-454.
14. Sternberg CN, Yagoda A, Bander NH, Whitmore WF Jr, Huffman JL, Fleisher M, Melamed MR, Fanucchi MP, Hollander P and Vaughan ED Jr: Phase I/II trial of intravesical methotrexate for superficial bladder tumors. *Cancer Chemother Pharmacol* 1986; **18**:265-269.
15. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, Bander NH, Finstad CL, Cordon-Cardo C, Klotz LH, Old LJ and Rubin RH: Monitoring of renal proximal tubular injury in transplantation with a monoclonal antibody-based assay for the adenosine deaminase-binding protein. *Transplant Proc* 1986; **18**:716-718.
16. Bander NH: Monoclonal antibodies. *In: American Urological Association Update*, Ball TP Jr, Novick DE, eds. (AUA Office of Education, Houston, TX) 1986.
17. Bander NH: Monoclonal antibodies and the diagnosis and treatment of bladder cancer. *In: Bladder Cancer: Future Directions for Treatment*, Yagoda A, ed. (John Wiley & Sons, NY, NY) 1986.
18. Bander NH and Klotz LH: Tumor immunology: *In: Urologic Oncology*, Graham S Jr, ed. (Raven Press, NY, NY) 1986.
19. Cordon-Cardo C, Finstad CL, Bander NH, Old LJ and Melamed MR: Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. *Am J Pathol* 1987; **126**:269-284.
20. Tolkoff-Rubin NE, Thompson RE, Piper DJ, Hansen WP, Bander NH, Cordon-Cardo C, Finstad CL, Klotz LH, Old LJ and Rubin RH: Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase-binding protein. *Nephrol Dialysis Transplant* 1987; **2**:143-148.

21. Kantor RRS, Bander NH, Finstad CL, Graf LH Jr, Lloyd KO, Old LJ and Albino AP: DNA-mediated gene transfer of a human cell surface 170-kilodalton glycoprotein. Evidence for association with an endogenous murine protein. *J Biol Chem* 1987; **262**:15166-15171.
22. Carter HB, Amberson JB, Bander NH, Badalment R, Gorelick J, Vaughan ED Jr and Whitmore WF Jr: Newer diagnostic techniques for bladder cancer. *Urol Clin N Amer* 1987; **14**(4):763-769.
23. Bander NH: Monoclonal antibodies: State of the art. *J Urol* 1987; **137**:603-612.
24. Klotz LH and Bander NH: Monoclonal antibodies and urologic oncology: Antigenic expression on genitourinary tumors. In: *Genitourinary Cancer*, Ratliff TL, Catalona WJ, eds. (Martinus Nijhoff Publishers, Boston, MA) 1987.
25. Weir EC, Insogna KL, Brownstein DG, Bander NH and Broadus AE: In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. *J Clin Invest* 1988; **81**(3):818-821.
26. Bander NH: Continent urinary diversion in the treatment of bladder cancer. *New Developments in Medicine* 1988; **2**:65-81.
27. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Barton DE, Francke U and Broadus AE: Identification of a complementary DNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. *Proc Natl Acad Sci USA* 1988; **85**:597-601.
28. Sternberg C, Yagoda A, Scher H, Watson R, Herr H, Morse M, Sogani P, Vaughan ED Jr, Bander NH, Weiselberg L, Geller N, Hollander P, Lipperman R, Fair WR and Whitmore WF Jr: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. *J Urol* 1988; **139**:461-469.
29. Ikeda K, Mangin M, Dreyer B, Webb A, Posillico J, Stewart A, Bander NH, Weir E, Insogna K and Broadus AE: Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. *J Clin Invest* 1988; **81**:2010-2014.
30. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander NH, Geller N, Fair WR and Whitmore WF Jr: Chemotherapeutic management of invasive bladder carcinoma. *Eur Urol* 1988; **14**(suppl):19-20.

31. Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr, Oettgen HF, Melamed MR and Old LJ: Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. *Cancer Res* 1989; **49**:6774-6780.
32. Sternberg C, Yagoda A, Scher HI, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander NH et al.: M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. *Cancer* 1989; **64**:2448-2458.
33. Nanus DM, Ebrahaim SAD, Bander NH, Real FX, Pfeffer LM, Shapiro JR and Albino AP: Transformation of human kidney proximal tubule cells by *ras*-containing retroviruses. Implications for tumor progression. *J Exp Med* 1989; **169**:953-972.
34. Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, Bander NH, Rubin AL and Stenzel KH: A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion of interleukin-2. *J Clin Oncol* 1989; **7**:1885-1891.
35. Yagoda A and Bander NH: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. *Urol Int* 1989; **44**:338-345.
36. Bander NH: ed. Renal cell carcinoma. In: *Seminars in Urology*, vol 7, nos 3 and 4 (WB Saunders, Philadelphia, PA), 1989.
37. Ebert T and Bander NH: Kidney-derived cell lines. *Seminars in Urology* 1989; **7**:247-251.
38. Bander NH: Monoclonal antibodies to renal cancer antigens. *Seminars in Urology* 1989; **7**:264-270.
39. Bander NH: Ureteral stent for nonrefluxing, continent urinary diversions reduces complications and hospitalization for patients. *Urol* 1990; **35**:64-67.
40. Nanus DM, Mentle IR, Motzer RJ, Bander NH and Albino AP: Infrequent *ras* oncogene point mutations in renal cell carcinoma. *J Urol* 1990; **143**:175-178.
41. Nanus DM, Pfeffer LM, Bander NH, Bahri S and Albino AP: Anti-proliferative and anti-tumor effect of alpha-interferon in renal carcinoma: correlation to the expression of kidney associated differentiation glycoprotein. *Cancer Res* 1990; **50**:4190-4194.
42. Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of renal cancer and normal kidney cell lines. *Cancer Res* 1990; **50**:5531-5536.

43. Rettig WJ, Triche TJ and Bander NH: Somatic cell genetic analysis of human cell surface antigens 5.1H11 and F35/9 (gp45). *Genomics* 1990; 6:178-183.
44. Libby DM, Bander NH, Altorki NK, Gold J, Pitts WR Jr and Frankel SS: Simultaneous pulmonary and renal malignancy. *Chest* 1990; 98:153-156.
45. Kerr L, Huntcoo C, Donohue J, Leibson PJ, Bander NH, Ghose T, Luner SJ, Vessella R and McKean DJ: Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells in *in vitro* activated lymphocytes. *J Immunol* 1990; 44:4060-4067.
46. Bander NH: Monoclonal antibodies to renal cancer antigens. *Eur Urol* 1990; 18:10-12.
47. Ebert T and Bander NH: Immunodiagnosis of renal cancer. In: *Immunodiagnosis of Cancer*, Mercer DW, Herberman RB, eds. (Marcel Dekker, New York, NY) 1990; pp. 469-484.
48. Sheinfeld J, Cordon-Cardo C and Bander NH: Immunodiagnosis of bladder cancer. In: *Immunodiagnosis of Cancer*, Mercer DW, Herberman RB, eds. (Marcel Dekker, New York, NY) 1990; pp. 485-500.
49. Ebert T, Ackerman R and Bander NH: Biologische marker beim nierenzellkarzinom. *Urologie* 1990; 29:65-70.
50. Gulmi FA and Bander NH: Managing carcinoma in situ of the bladder. *Contemp Urol* 1990; 1:45-52.
51. Bander NH: Initial results with slightly modified Koch pouch. *Urol* 1991; 37:100-105.
52. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH and Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. *Cancer Res* 1992; 52:6229-6236.
53. Bander NH, Gastl G, Nanus DM, Pfeffer LM, Finstad CL and Albino AP: Anti-proliferative and anti-tumor effect of α -interferon in renal cell carcinoma: Correlation with the expression of a kidney associated differentiation glycoprotein. In: *Basic and Clinical Research on Renal Cell Carcinoma*, Staehler G, Pomer S, eds. (Springer-Verlag, Heidelberg, Germany) 1992; pp. 115-120.
54. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn R, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *J Clin Oncol* 1993; 11:738-750.

55. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH and Rubin SC: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. *Brit J Haematol* 1993; **83**:433-441.
56. Gastl G, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen N, Albino AP and Bander NH: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. *Int J Cancer* 1993; **55**:96-101.
57. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH and Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. *Proc Natl Acad Sci USA* 1993; **90**:7069-7073.
58. Holt EH, Vasavada RC, Bander NH, Broadus AE and Philbrick WM: Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. *J Biol Chem* 1993; **268**:20639-20645.
59. Gastl G, Bander NH, Frick J, Huber C and Aulitzky W: Immunotherapie des metastasierten nierenzellkarzinomas mit rekombinantem interferon-gamma. In: *Immunotherapie in der Uroonkologie*, Rubben H, Goepel M, Schmitz-Drager B, eds. (Springer-Verlag, Heidelberg, Germany) 1993; pp. 46-55.
60. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan D-S R, Florence C, Pozzatti R, Walther MM, Bander NH et al.: VHL tumor suppressor gene mutations in renal cell carcinoma tumorigenesis. *Nature Genet* 1994; **7**:85-90.
61. Bander NH: Current status of monoclonal antibodies for imaging and therapy of prostate cancer. In: *Seminars in Oncology*, Scher H., ed. (WB Saunders, New York, NY) 1994; **21**:607-612.
62. Berger MF, Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, van Fleuren G, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. In: *Biology of Renal Cell Carcinoma*, Bukowski RM, Finke JH, Klein EA, eds. (Springer-Verlag, New York, NY) 1995; pp. 257-267.
63. Bander NH: Immunology of renal cancer. In: *Comprehensive Textbook of Genitourinary Oncology*, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. (Williams & Wilkins, Philadelphia, PA) 1995; pp. 171-178.
64. Kinouchi T, Bander NH and Kotake T: Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement-dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity. *J Urol* 1995; **154**:288-292.

65. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W and Bander NH: MHC Class I and Class II expression in renal cell carcinoma and modulation by interferon-gamma. *J Urol* 1996; **155**:361-367.
66. Motzer RJ, Bander NH and Nanus DM: Renal cell carcinoma. *N Engl J Med* 1996; **335**:865-875.
67. Shemtov MM and Bander NH: Immunologic approaches to genitourinary malignancies. In *Campbell's Urology Update* (Patrick C Walsh, Alan B Retik, Thomas A Stamey, E Darracott Vaughan and Alan J Wein, eds.) Philadelphia, PA. **20**:1-11, 1996.
68. McKiernan JM, Buttyan R, Bander NH, Stifelman MD, Katz AE, Chen M-W, Olsson CA and Sawczuk IS: Expression of the tumor-associated gene MN; a potential biomarker for human renal cell carcinoma. *Cancer Res* 1997; **57**:2362-2365.
69. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna Jr MG, Silberman SR and Butman BT: A multicenter trial evaluation of the Aura-Tek FDP test for detection and monitoring of bladder cancer. *J Urol* 1997; **158**:801-805.
70. Motzer RJ, Bander NH and Nanus DM: Letter to the Editor. *N Engl J Med* 1997; **336**:810-811.
71. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B and Bander NH: Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. *Cancer Res* 1997; **57**:3629-3634.
72. Bander NH, Yao D, Liu H, Chen Y-T, Steiner M, Zuccaro W and Moy P: MHC Class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. *The Prostate* 1997; **33**:233-239.
73. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. *Classic Papers and Current Comments* 1997; **2**:331-344.
74. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, Bander NH, Albino AP, and Reuter VE: Aminopeptidase A expression and enzymatic activity in primary human renal cancers. *International J Oncology* 1998; **13**(2):261-267.
75. Liu H, Rajasekaran A.K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., and Bander N.H.: Constitutive and Antibody-Induced Internalization of Prostate Specific Membrane Antigen. *Cancer Res* 1998; **58**:4055-4060.

76. Divgi C.R., Bander N.H., Scott A.M., O'Donoghue, Sgouros G, Welt S., Finn R.D., Morrissey F., Capitelli P., Williams J.M., Deland D., Nakhre A., Oosterwijk E., Gulec S., Graham M.C., Larson S.M., Old L.J.: Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (mAb) G250 in metastatic renal carcinoma. *Clin Cancer Res* 1998;4:2729-2739.
77. Prewett M, Rothman M, Waksal H, Feldman M, Bander N.H., and Hicklin D.J.: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. *Clin Cancer Res* 1998;4:2957-2966.
78. Ebert T, Anastasiadis A, Bander NH: Renal Cell Cancer in *Human Cell Culture* (J.R.W. Masters and B. Palsson eds.). Kluwer Academic Publishers 1999;1:231-249.
79. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander, NH, Novick AC, and Finke JH: Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. *Clin Cancer Res* 1999;5:1219-1229.
80. Rajasekaran SA, Ball WJ Jr, Bander NH., Liu H, Pardee JD, and Rajasekaran AK: Reduced expression of β -subunit of Na, K-ATPase in human clear-cell renal-cell carcinoma. *J Urology*, in press.
81. Suh CI, Bander, NH, Helm K, and Glode LM: A method for isolation of prostatic epithelial cells from seminal fluid. *Biotechniques*, submitted.
82. Rajasekaran SA, Palmer LG, Ball WJ Jr, Bander NH, and Rajasekaran AK: Multiple functions of β -subunit of Na,K-ATPase: Role in tumor cell invasion suppression. *Science*, submitted.
83. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT and Old LJ: Serum Antibody Recognition With Renal-Cell Carcinoma. *Submitted*
84. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Finke JH: Dead or dying: Necrosis vs. apoptosis in caspase deficient human renal cell carcinoma. *Cancer Res*, in press 1999.
85. McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS: The detection of renal cancer cells in the peripheral blood via an enhanced RT-PCR assay for MN/CA9. *Cancer*, submitted and accepted 1999.
86. Chang SS, Bander NH, Heston WDW: Monoclonal Antibodies: Will they become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen. *Current Review In Urology*, submitted 1999.

87. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS. and Gaudin PB: Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA)¹ expression in tumor-associated neovasculature. *submitted.*
88. Bander NH: Monoclonal antibodies for imaging and therapy of prostate cancer. Klein E (ed). *Management of Prostate Cancer, Humana Press. submitted.*
89. Gong MC, KrauseA, Latouche JB, Heston WDW, Bander NH & Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen efficiently and specifically lyse prostate cancer cells. *Neoplasia. in press 1999.*